NEW YORK, Sept. 24 – The Genetics Company and Discovery Partners have partnered to identify potential drug targets for colon cancer, the companies said on Monday.

Discovery Partners, of San Diego, will screen thousands of chemical compounds for their ability to inhibit a protein that The Genetics Company has in previous studies linked to colon cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.